Sciatic nerve atrophy as a predictor of impaired wound healing in patients with chronic limb-threatening ischemia following endovascular therapy: A prospective pilot study - Report - MDSpire
Advertisement
Sciatic nerve atrophy as a predictor of impaired wound healing in patients with chronic limb-threatening ischemia following endovascular therapy: A prospective pilot study
Atrophy of the Sciatic Nerve as an Indicator of Wound Healing Complications
Overview
This pilot study investigates the role of sciatic nerve atrophy (SNA) as a predictive factor for adverse wound outcomes (AWO) in patients with chronic limb-threatening ischemia (CLTI) following endovascular treatment (EVT). The findings suggest that SNA may serve as a reliable biomarker for identifying patients at risk of impaired wound healing and other complications post-EVT.
Background
Chronic limb-threatening ischemia (CLTI) is a severe manifestation of peripheral artery disease, often leading to significant complications such as impaired wound healing and major amputation. Endovascular therapy (EVT) is a common treatment option, yet many patients still experience adverse wound outcomes. Identifying reliable biomarkers like sciatic nerve atrophy could enhance risk stratification and management strategies for these patients.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
Sciatic nerve atrophy (SNA) was identified as a potential risk factor for impaired wound healing (IWH) and adverse wound outcomes (AWO) in CLTI patients.
The study was conducted as a prospective, observational pilot investigation at Peking University First Hospital.
Inclusion criteria for participants included adults with CLTI and lower-limb tissue loss without prior major amputation.
Standardized wound care procedures were uniformly administered to all participants regardless of group classification.
The study aimed to establish SNA as a simple, reliable biomarker for predicting AWO and amputation-free survival (AFS).
Clinical Implications
The identification of sciatic nerve atrophy as a predictive factor for adverse wound outcomes may assist clinicians in stratifying risk and tailoring wound management strategies for patients with CLTI. This could lead to improved patient outcomes and resource utilization in managing complications post-endovascular treatment.
Conclusion
The study highlights the potential of sciatic nerve atrophy as a biomarker for predicting adverse wound outcomes in CLTI patients following EVT. Further research is warranted to validate these findings and explore their clinical applications.
